The R4RA study investigated the best therapeutic option between rituximab vs. tocilizumab for patients with RA and previous inadequate response to anti-TNF, by assessing whether molecular and cellular signatures of B cells predicted a better response to rituximab. Here, TNF is linked to rheumatoid arthritis.